CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 329 · Search date 2026-07-11 · Methodology v0.6

Monolaurin,
does it really help with Antibacterial, antiviral, and immune support?

30-Second Summary
?
Evidence Grade ? · Safety unknown
In vitro antimicrobial and antiviral activity is not equivalent to evidence that an oral supplement prevents infection or improves immunity
What the
research shows
No efficacy trial was identified for oral monolaurin in infection prevention, infection treatment, or immune support. A randomized trial of 5% vaginal gel used a different route and indication and cannot be transferred to oral supplements. The target route has no direct human literature, resulting in a question-mark grade.
What the
ads claim
Product descriptions may translate bacterial and viral membrane effects in vitro into infection defense, viral suppression, or enhanced immunity. Oral human evidence has not tested that transfer.
*

Useful facts when choosing a product

  • Monolaurin is a monoester of lauric acid and glycerol and is not the same as coconut oil itself.
  • An effective concentration in vitro is not equivalent to a blood or tissue concentration after oral intake.
  • The published human randomized trial used a 5% vaginal gel, a different route from oral pellets or capsules.
  • Long-term safety and drug-interaction data for high-dose oral use are limited.
Gap Measurement · Verdict 329 · ?
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 1992 study by Schlievert and colleagues inhibited growth and exotoxin production in cultured streptococci and staphylococci. The 2020 study by Welch and colleagues reported virucidal activity against enveloped viruses, including HIV-1, in culture systems. The 2020 multicenter trial by Mancuso and colleagues gave 5% monolaurin vaginal gel or placebo for three days to 109 women; clinical cure was 17% versus 25%, with no significant difference. This was not an oral product and did not evaluate systemic infection prevention or immune support.

02

Why this is classified as ?

The grade is a question mark because no controlled human literature tested the target efficacy of oral monolaurin. A single null topical trial was not generalized into an F for all oral infection claims, and positive in vitro results were not upgraded into human efficacy.

Counterpoint. A researchable biological signal remains in local microbial settings and selected formulations. This assessment separates that signal from systemic oral efficacy.

Rejudgment record. Reassessment (cross-check reflected) — No directly controlled human efficacy literature for oral monolaurin in infection prevention, infection treatment, or immune support; positive in vitro work and a null topical vaginal-gel RCT do not establish oral efficacy

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Mancuso AC et al. 2020Multicenter double-blind randomized placebo-controlled trial109UnknownAmsel clinical cure, Nugent score, and adverse eventsClinical cure was 17% versus 25%; monolaurin gel was not superior to placebo.Indirect human evidence
Welch JL et al. 2020In vitro virology studyU.S. public and academic researchInfectivity of enveloped virusesReduced infectivity of enveloped viruses, including HIV-1, in culture systems.Preclinical
Schlievert PM et al. 1992In vitro bacteriology studyAcademic researchBacterial growth and exotoxin productionInhibited growth and exotoxin production in selected gram-positive bacteria.Preclinical
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-11).

Mancuso AC, Widdice LE, Hughes BL, et al. 2020. Five Percent Monolaurin Vaginal Gel for the Treatment of Bacterial Vaginosis: A Randomized Placebo-Controlled Trial. J Low Genit Tract Dis. 24(3):277-283. PMID: 32379102. DOI: 10.1097/LGT.0000000000000543.
checked
Welch JL, Xiang J, Okeoma CM, Schlievert PM, Stapleton JT. 2020. Glycerol Monolaurate, an Analogue to a Factor Secreted by Lactobacillus, Is Virucidal against Enveloped Viruses, Including HIV-1. mBio. 11(3):e00686-20. PMID: 32371599. DOI: 10.1128/mBio.00686-20.
checked
Schlievert PM, Deringer JR, Kim MH, Projan SJ, Novick RP. 1992. Effect of glycerol monolaurate on bacterial growth and toxin production. Antimicrob Agents Chemother. 36(3):626-631. PMID: 1622174. DOI: 10.1128/AAC.36.3.626.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Monolaurin (glycerol monolaurate) × Antibacterial, antiviral, and immune support Evidence Grade ? card
[Chamgap] Monolaurin (glycerol monolaurate) × Antibacterial, antiviral, and immune support — Evidence Grade ?. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/general/monolaurin-antimicrobial-antiviral-immunity/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.